RxDoctor Payments Data

David Casey, MD

Interventional Cardiology · Snellville, GANPI 1447559604

Payments from drug & device makers

$7,899in general payments, 2019–2025

Across 225 payments — averaging $35.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$783
  • Johnson & Johnson$693
  • Cardiovascular Systems Inc.$524
  • Abiomed$426
  • Medtronic$393
  • plus $4K from 36 others

What the payments were for

  • Travel & lodging$1,17115%
  • Food & beverage$6,52583%
  • Education$2023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,899 in reported general payments places this provider in the 45th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$146,281
Medicare patients
681
Services billed
1,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$273,322
JardianceEmpagliflozin94$95,824
EntrestoSacubitril/Valsartan67$71,415
Repatha SureclickEvolocumab28$43,956
XareltoRivaroxaban33$38,362
FarxigaDapagliflozin Propanediol18$22,838
MultaqDronedarone Hcl13$18,993
BrilintaTicagrelor27$16,375
Atorvastatin Calcium357$3,482
Metoprolol Succinate327$2,749
Amiodarone Hcl38$2,566
Ezetimibe116$2,272
Rosuvastatin Calcium162$2,162
Isosorbide Dinitrate22$2,079
Carvedilol245$1,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$340$273,322280 claims
Boehringer IngelheimJardiance$154$95,82494 claims
NovartisEntresto$348$71,41567 claims
AstraZenecaFarxiga, Brilinta$338$39,21345 claims
Johnson & JohnsonXarelto$693$38,36233 claims
Sanofi-aventis U.S. LLCMultaq$14$18,99313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →